'An Open-label Study of Patient Preference With Monthly Bonviva Therapy in Women With Post-menopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate.
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms BONCURE
- Sponsors Roche
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 17 Jul 2009 Planned end date changed from Jul 2008 to Oct 2008 as reported by ClinicalTrials.gov.
- 23 Jan 2008 Status changed from recruiting to in progress.